Blog
About

130
views
0
recommends
+1 Recommend
0 collections
    1
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors.

          Related collections

          Author and article information

          Journal
          N. Engl. J. Med.
          The New England journal of medicine
          New England Journal of Medicine (NEJM/MMS)
          1533-4406
          0028-4793
          Aug 15 2002
          : 347
          : 7
          Affiliations
          [1 ] Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA 02115, USA.
          Article
          347/7/472
          10.1056/NEJMoa020461
          12181401

          Comments

          Comment on this article